Transplant-Associated Microangiopathy in Patients Receiving Tacrolimus Following Allogeneic Stem Cell Transplantation: Risk Factors and Response to Treatment

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 4, 2007, Pages 469-477

  Oran, Betul ^a   Donato, Michele ^a   Aleman, Ana ^a   Hosing, Chitra ^a   Korbling, Martin ^a   Detry, Michelle A ^a   Wei, Caimiao ^a   Anderlini, Paolo ^a   Popat, Uday ^a   Shpall, Elizabeth ^a   Giralt, Sergio ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Graft versus host disease; Tacrolimus; Transplant associated microangiopathy

Indexed keywords

ANTIINFECTIVE AGENT; BUSULFAN; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; GLUCOCORTICOID; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BLEEDING; BONE MARROW CANCER; BRAIN DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATALITY; FEMALE; GENDER; GRAFT INFECTION; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; PLASMAPHERESIS; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; VIRUS INFECTION; WHOLE BODY RADIATION;

ADULT; ANEMIA, HEMOLYTIC; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PLASMA EXCHANGE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; THROMBOCYTOPENIA; TRANSPLANTATION, HOMOLOGOUS;

EID: 33947240963     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.11.020     Document Type: Article

References (35)

1. Holler E., Kolb H.J., Hiller E., et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 73 (1989) 2018-2024
2. George J.N., Li X., McMinn J.R., Terrell D.R., Vesely S.K., and Selby G.B. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 44 (2004) 294-304
3. Pettitt A.R., and Clark R.E. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 14 (1994) 495-504
4. Zeigler Z.R., Shadduck R.K., Nemunaitis J., Andrews D.F., and Rosenfeld C.S. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 15 (1995) 247-253
5. Greeno E.W., Bach R.R., and Moldow C.F. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 75 (1996) 281-289
6. Bombeli T., Karsan A., Tait J.F., and Harlan J.M. Apoptotic vascular endothelial cells become procoagulant. Blood 89 (1997) 2429-2442
7. Bombeli T., Schwartz B.R., and Harlan J.M. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood 93 (1999) 3831-3838
8. Kwaan H.C., and Soff G.A. Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 34 (1997) 159-166
9. Ruutu T., Hermans J., Niederwieser D., et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 118 (2002) 1112-1119
10. Martinez M.T., Bucher C., Stussi G., et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 36 (2005) 993-1000
11. Dlott J.S., Danielson C.F., Blue-Hnidy D.E., and McCarthy L.J. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Therap Apher Dial 8 (2004) 102-111
12. Qu L., and Kiss J.E. Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost 31 (2005) 691-699
13. Furlan M., Robles R., Solenthaler M., Wassmer M., Sandoz P., and Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89 (1997) 3097-3103
14. Tsai H.M., and Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 (1998) 1585-1594
15. van der Plas R.M., Schiphorst M.E., Huizinga E.G., et al. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 93 (1999) 3798-3802
16. Zoja C., Furci L., Ghilardi F., Zilio P., Benigni A., and Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest 55 (1986) 455-462
17. Ruutu T., Barosi G., Benjamin R.J., et al. Diagnostic criteria for hematopoietic stem cell transplantation-associated microangiopathy (TAM): results of a consensus process by an international working group. Blood 106 (2005) 400
18. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825-828
19. Sullivan K.M., Agura E., Anasetti C., et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28 (1991) 250-259
20. Gooley T.A., Leisenring W., Crowley J., and Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18 (1999) 695-706
21. Brown Z., Neild G.H., Willoughby J.J., Somia N.V., and Cameron S.J. Increased factor VIII as an index of vascular injury in cyclosporine nephrotoxicity. Transplantation 42 (1986) 150-153
22. Rock G.A. Management of thrombotic thrombocytopenic purpura. Br J Haematol 109 (2000) 496-507
23. Miller D.P., Kaye J.A., Shea K., et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology 15 (2004) 208-215
24. Fuge R., Bird J.M., Fraser A., et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 113 (2001) 58-64
25. Paquette R.L., Tran L., and Landaw E.M. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant 22 (1998) 351-357
26. Seeber C., Hiller E., Holler E., and Kolb H.J. Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNF alpha)-release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT). Thromb Res 66 (1992) 373-383
27. Bernardo A., Ball C., Nolasco L., Moake J.F., and Dong J.F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104 (2004) 100-106
28. Biedermann B.C., Sahner S., Gregor M., et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359 (2002) 2078-2083
29. Shimoni A., Yeshurun M., Hardan I., Avigdor A., Ben-Bassat I., and Nagler A. Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: the incidence is not reduced. Biol Blood Marrow Transplant 10 (2004) 484-493
30. van Besien K., Bartholomew A., Stock W., et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant 26 (2000) 445-449
31. Kornacker M., Luft T., Ho A.D., and Schaefer H.J. Thrombotic microangiopathy after combined autografting-allografting for multiple myeloma - report of three cases. Eur J Haematol 74 (2005) 250-253
32. Corradini P., Tarella C., Olivieri A., et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99 (2002) 75-82
33. Eissner G., Multhoff G., Gerbitz A., et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 100 (2002) 334-340
34. Zent R., Katz A., Quaggin S., et al. Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A. Clin Nephrol 47 (1997) 181-186
35. Roy V., Rizvi M.A., Vesely S.K., and George J.N. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 27 (2001) 641-646